AstraZeneca to pay up to $4.1bn for BMS share of diabetes JV
This article was originally published in Scrip
Executive Summary
AstraZeneca is acquiring Bristol-Myers Squibb's share of their global diabetes alliance assets for $2.7bn up front and up to a further $1.4bn in regulatory, launch and sales-related payments.